Medtronic’s Endeavor Stent Hits Primary Endpoint In Pivotal Trial
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's Endeavor zotarolimus-eluting stent is as effective as Boston Scientific's Taxus paclitaxel-eluting stent in the ENDEAVOR IV trial, Medtronic announced July 2
You may also be interested in...
Medtronic Bullish About Endeavor’s Chances In U.S. Market
Medtronic is confident being the late-comer to the U.S. drug-eluting stent market will not hinder its Endeavor zotarolimus-eluting coronary stent gaining market share
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.